Palatin Technologies(PTN) - 2025 Q1 - Quarterly Results

EX-99.1 2 ptn_ex991.htm EX-99.1 EXHIBIT 99.1 Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results · Obesity programs: o Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates o Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ■ Patient enrollment completed October 2024 ■ Topline results expected 1Q calendar year 2025 o Multiple clinical trials targeted in calendar year 20 ...